Xingfeng Bao

Xingfeng Bao's work experience includes holding the position of VP of Biology at GV20 Therapeutics starting in 2023. Before that, they worked at H3biomedicine Inc as the Executive Director of Discovery Biology and Pharmacology from January 2019. At H3biomedicine, they established an immuno-oncology discovery biology engine and managed an in vivo pharmacology platform. Xingfeng made significant contributions such as building an immuno-oncology pipeline, filing INDs, achieving clinical proof-of-principle for certain compounds, and leading a strategic collaboration program with Bristol-Myers-Squib. Prior to H3biomedicine, Xingfeng Bao worked at Eisai US as the Senior Director of Cancer Immunotherapy Discovery from May 2011 to December 2018. There, they held various roles and led multidisciplinary project teams. Xingfeng also worked at Sanford|Burnham Medical Research Institute as a Staff Scientist from July 2005 to April 2011. Xingfeng Bao's earliest work experience was as a JSPS postdoctoral fellow at Kobe Pharmaceutical University from October 2002 to June 2005, where they focused on molecular characterization of glycan-mediated growth factor signaling.

Xingfeng Bao obtained a Ph.D. in Chemistry and Pharmacology from the Graduate School of Chinese Academy of Sciences. This educational accomplishment took place from 1997 to 2002.